Anti-fragment C from tetanus toxin antibody enzyme-linked immunosorbent assay results

Christian Ottensmeier; Megan Bowers; Debbie Hamid; Tom Maishman; Scott Regan; Wendy Wood; Angelica Cazaly; Louise Stanton

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Ottensmeier C, Bowers M, Hamid D, et al. Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN). Southampton (UK): NIHR Journals Library; 2016 Apr. (Efficacy and Mechanism Evaluation, No. 3.3.)

Cover of Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN)

Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN).

Show details

Contents

< Prev Next >

Appendix 3Anti-fragment C from tetanus toxin antibody enzyme-linked immunosorbent assay results

Anti-FrC antibody ELISA results are shown as mean relative antibody units at each time point (0–23 weeks). Positive responses (shown highlighted in green) represent a greater than twofold, and significantly greater than pre-vaccination, baseline (p< 0.05, Dunnett’s multiple comparisons test). Blue shading represents no sample. The final column shows overall response, with a maximum fold increase relative to baseline.

FrC	Time point (weeks)																						Overall result
FrC	00	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	23	Overall result
1-C-005	0.4215	0.4151	0.6618	0.6491	0.8572	0.8491	0.7884	0.7357	0.8395	0.8159	0.8159		0.7603		0.7135	0.5409	0.5194	0.4560		0.6307	0.5164	0.5923	2.0
1-C-022	0.0517	0.0624	0.0899	0.4052	1.1441		1.4248	1.6481	1.7005	1.7878	1.7795	1.8024		1.2027	0.9147							0.7652	34.9
1-C-023	0.6330	0.5645	1.0376	1.0156	1.2872	1.2920	1.2381	1.8903	1.6056	1.7529		1.4973	1.4630	1.3148	1.0102							0.9034	3.0
2-C-002	1.5938	2.2106	4.4236	2.9914	3.6068	4.7370	3.1848	3.2868	2.8729	5.1475	4.5656		2.3297	4.5745	3.0819				3.1852	2.7010	3.3740		3.2
2-C-004	0.1043	0.1389	0.1340	0.0573	0.1130	0.2688	0.2195	0.2440	0.2212	0.4068	0.3736	0.1449		0.1633	0.0702			0.0691					3.9
2-C-007	0.0854	0.1092	0.1098	0.1417	0.3030	0.4984	0.6170	0.7719	0.4890	0.8262	0.7443	0.3447											9.7
2-C-010	0.4321	0.5565	1.0132	1.2200	0.9896	1.4916	1.4232	1.4452	1.3271	1.3318	1.2191	0.8340	0.7065			0.6568	0.6074	0.7267					3.5
2-C-012	0.6950	0.7023	1.2529	1.1530	1.1180	1.0267	1.1176	1.3059	1.6607	1.6134	1.5593	1.2250	1.8651	1.0415									2.7
2-C-013	0.1304	0.1458	0.3887	0.3314	0.3412	0.4077	0.4102	0.4713	0.4341	0.4839					0.2557								3.7
2-C-014	0.3324	0.3583	1.0392	1.0211	1.1308	1.0485	1.0133	1.2261	1.2952	1.2738					0.5880								3.9
3-C-017	NA										0.5324	0.4440	0.4829	0.3703									NA
Response frequency	0	0	4	4	8	8	6	8	8	9	6	3	2	3	1	0	0	0	0	0	1	1	10/11

: NA, not applicable.

Copyright © Queen’s Printer and Controller of HMSO 2016. This work was produced by Ottensmeier et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK355749

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Ottensmeier C, Bowers M, Hamid D, et al. Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN). Southampton (UK): NIHR Journals Library; 2016 Apr. (Efficacy and Mechanism Evaluation, No. 3.3.) Appendix 3, Anti-fragment C from tetanus toxin antibody enzyme-linked immunosorbent assay results.
PDF version of this title (2.3M)

Other titles in this collection

Efficacy and Mechanism Evaluation

Recent Activity

Clear Turn Off Turn On

Anti-fragment C from tetanus toxin antibody enzyme-linked immunosorbent assay re...
Anti-fragment C from tetanus toxin antibody enzyme-linked immunosorbent assay results - Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN)

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN).

Appendix 3Anti-fragment C from tetanus toxin antibody enzyme-linked immunosorbent assay results

Views

Other titles in this collection

Recent Activity